

**SAFETY EVALUATION REPORT**  
**PROPOSED CHANGE OF CONTROL FOR BYPRODUCT MATERIALS LICENSE**  
**NUMBER 21-25912-01, D. NARLA, M.D., PC**

**DATE:** April 17, 2015

**DOCKET NO.:** 030-30553

**LICENSE NO.:** 21-25912-01

**LICENSEE:** D. Narla, M.D., PC  
44850 Mound Road  
Sterling Heights 48314

**TECHNICAL REVIEWER:** Bryan A. Parker, Health Physicist



**SUMMARY AND CONCLUSIONS**

D. Narla, M.D., PC is authorized by NRC License 21-25912-01 for the possession and use of byproduct material for medical use. The U. S. Nuclear Regulatory Commission (NRC) staff reviewed a request for consent to a direct license transfer submitted by D. Narla, M.D., PC, that would result from the corporation selling its assets to another corporation. The licensee, D. Narla, M.D., PC, indicated it would sell its assets to Advanced Cardiovascular Associates, PLC, which would also become the new name. Dr. Narla will continue to provide patient care as an employee of Advanced Cardiovascular Associates, PLC. The transaction was finalized on April 15, 2015. The direct transfer of control is described in Agency Documents Access and Management System (ADAMS) accession number ML15063A294.

The request for consent was reviewed by NRC staff for a direct change in control of a 10 CFR Part 30 license using the guidance in NUREG 1556, Volume 15, "Consolidated Guidance About Materials Licenses - Guidance About Changes of Control and About Bankruptcy Involving Byproduct, Source, or Special Nuclear Materials Licenses," dated November 2000. The NRC staff finds that the information submitted by D. Narla, M.D., PC, sufficiently describes and documents the transaction and commitments made by D. Narla, M.D., PC, and Advanced Cardiovascular Associates, PLC.

As required by 10 CFR 30.34 and section 184 of the Atomic Energy Act of 1954, as amended (the Act), NRC staff has reviewed the application and finds that the proposed change in control is in accordance with the Act. The staff finds that, after the change of control, Advanced Cardiovascular Associates, PLC will remain qualified to use byproduct material for the purpose requested, and will continue to have the equipment, facilities, and procedures needed to protect public health and safety, and promotes the security of licensed material.

**SAFETY AND SECURITY REVIEW**

According to data obtained from the NRC's Web-Based Licensing system (WBL), D. Narla, M.D., PC, has been an NRC licensee since May 10, 1988. The NRC conducted a main office inspection of D. Narla, M.D., PC, on November 3, 2014, and one Severity Level IV violation for failure to properly secure licensed material was identified during this inspection. The violation was corrected during the inspection and no response was required to the Notice of Violation.

The licensee stated that Advanced Cardiovascular Associates, PLC, (formerly D. Narla, M.D., PC - License No. 21-25912-01):

- A. will not change the Radiation Safety Officer listed in the NRC license;
- B. will not change the personnel involved in licensed activities;
- C. will not change the locations, facilities, and equipment authorized in the NRC license;
- D. will not change the radiation safety program authorized in the NRC license;
- E. will not change the organization's name listed in the NRC license; and
- F. will keep regulatory required surveillance records and decommissioning records.

Advanced Cardiovascular Associates, PLC is solely owned by Luay Sayed, M.D. Dr. Sayed was formerly listed as an authorized user on NRC License No. 21-26263-01 during the period of August 25, 2008 to December 10, 2008. Therefore, for security purposes, Advanced Cardiovascular Associates, PLC is considered a known entity following the guidance provided by the NRC's Office of Federal and State Materials and Environmental Management Programs (FSME) 'Checklist to provide a basis for confidence that radioactive materials will be used as specified on the license', September 3, 2008 revision. The purpose of this checklist is for the NRC to obtain reasonable assurance from new license applicants or NRC licensees transferring control of licensed activities that the licensed material will be used for its intended purpose and not for malevolent use.

Advanced Cardiovascular Associates, PLC, is not required to have decommissioning financial assurance based on the types and amount of material authorized in License No. 21-25912-01.

## **REGULATORY FRAMEWORK**

D. Narla, M.D., PC's License No. 21-25912-01, was issued under 10 CFR Part 30, Rules of General Applicability to Domestic Licensing of Byproduct Material. The Commission is required by 10 CFR 30.34 to determine if the change of control is in accordance with the provisions of the Act and give its consent in writing.

10 CFR 30.34(b) states: "No license issued or granted pursuant to the regulations in this part and parts 31 through 36, and 39 nor any right under a license shall be transferred, assigned or in any manner disposed of, either voluntarily or involuntarily, directly or indirectly, through transfer of control of any license to any person, unless the Commission shall, after securing full information, find that the transfer is in accordance with the provisions of the Act and shall give its consent in writing."

As previously indicated, the staff evaluation is based on guidance in NUREG-1556, Volume 15. As discussed in NUREG-1556, Volume 15, NRC is generally using the term "change of control" rather than the statutory term "transfer" to describe the variety of events that could require prior notification and written consent of the NRC. The central issue is whether the authority over the license has changed. D. Narla, M.D., PC's request for consent describes a

direct change of control resulting from one corporation selling all assets to another corporation and, as such, the transfer requires NRC consent.

### **DESCRIPTION OF TRANSACTION**

The transaction is described in ADAMS accession number ML15063A294. After completion of the sell on April 15, 2015, Advanced Cardiovascular Associates, PLC, continued as the licensee and remains in control of all licensed activities under Materials License No. 21-25912-01. The NRC staff finds that the request for consent adequately provides a complete and clear description of the transaction, and is consistent with the guidance provided in Appendix F of NUREG-1556, Volume 15.

### **TRANSFeree'S COMMITMENT TO ABIDE BY THE TRANSFEROR'S COMMITMENTS**

The NRC staff finds that the information submitted by D. Narla, M.D., PC sufficiently describes and documents the commitments made by D. Narla, M.D., PC, and Advanced Cardiovascular Associates, PLC, and is consistent with the guidance in NUREG-1556, Volume 15.

### **ENVIRONMENTAL REVIEW**

An environmental assessment for this action is not required since this action is categorically excluded under 10 CFR 51.22(c)(21).

### **CONCLUSION**

The staff has reviewed the request for consent submitted with regard to an direct change of control of Byproduct Materials License No. 21-25912-01 and approves the application pursuant to 10 CFR 30.34(b).

The submitted information sufficiently describes the transaction; documents the understanding of the license and commitments; demonstrates that personnel have the experience and training to properly implement and maintain the license and that they will maintain the existing records; And, in the future, will abide by all existing commitments to the license, consistent with the guidance in NUREG-1556, Volume 15.

Therefore, the staff concludes that the proposed change in control would not alter the previous findings, made under 10 CFR Part 30, that licensed operations will not be inimical to the common defense and security, or to the health and safety of the public.